FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3025282612> ?p ?o ?g. }

• W3025282612 endingPage "1517" @default.
• W3025282612 startingPage "1505" @default.
• W3025282612 abstract "The aim of this study was to compare, using results from the multicenter SPINS (Stress CMR Perfusion Imaging in the United States) study, the incremental cost-effectiveness of a stress cardiovascular magnetic resonance (CMR)–first strategy against 4 other clinical strategies for patients with stable symptoms suspicious for myocardial ischemia: 1) immediate x-ray coronary angiography (XCA) with selective fractional flow reserve for all patients; 2) single-photon emission computed tomography; 3) coronary computed tomographic angiography with selective computed tomographic fractional flow reserve; and 4) no imaging. Stress CMR perfusion imaging has established excellent diagnostic utility and prognostic value in coronary artery disease (CAD), but its cost-effectiveness in current clinical practice has not been well studied in the United States. A decision analytic model was developed to project health care costs and lifetime quality-adjusted life years (QALYs) for symptomatic patients at presentation with a 32.4% prevalence of obstructive CAD. Rates of clinical events, costs, and quality-of-life values were estimated from SPINS and other published research. The analysis was conducted from a U.S. health care system perspective, with health and cost outcomes discounted annually at 3%. Using hard cardiovascular events (cardiovascular death or acute myocardial infarction) as the endpoint, total costs per person were lowest for the no-imaging strategy ($16,936) and highest for the immediate XCA strategy ($20,929). Lifetime QALYs were lowest for the no-imaging strategy (12.72050) and highest for the immediate XCA strategy (12.76535). The incremental cost-effectiveness ratio for the CMR-based strategy compared with the no-imaging strategy was $52,000/QALY, whereas the incremental cost-effectiveness ratio for the immediate XCA strategy was $12 million/QALY compared with CMR. Results were sensitive to variations in model inputs for prevalence of disease, hazard rate ratio for treatment of CAD, and annual discount rate. Prior to invasive XCA, stress CMR can be a cost-effective gatekeeping tool in patients at risk for obstructive CAD in the United States. (Stress CMR Perfusion Imaging in the United States [SPINS] Study; NCT03192891" @default.
• W3025282612 created "2020-05-21" @default.
• W3025282612 creator A5002476423 @default.
• W3025282612 creator A5018162304 @default.
• W3025282612 creator A5021117032 @default.
• W3025282612 creator A5027172114 @default.
• W3025282612 creator A5028438824 @default.
• W3025282612 creator A5031206155 @default.
• W3025282612 creator A5033266914 @default.
• W3025282612 creator A5034534199 @default.
• W3025282612 creator A5037038264 @default.
• W3025282612 creator A5039107780 @default.
• W3025282612 creator A5043658281 @default.
• W3025282612 creator A5043965596 @default.
• W3025282612 creator A5046806152 @default.
• W3025282612 creator A5049270829 @default.
• W3025282612 creator A5055948063 @default.
• W3025282612 creator A5056428329 @default.
• W3025282612 creator A5059528272 @default.
• W3025282612 creator A5061713920 @default.
• W3025282612 creator A5062965204 @default.
• W3025282612 creator A5065965358 @default.
• W3025282612 creator A5071887791 @default.
• W3025282612 creator A5075076342 @default.
• W3025282612 creator A5084430398 @default.
• W3025282612 date "2020-07-01" @default.
• W3025282612 modified "2023-09-26" @default.
• W3025282612 title "Cost-Effectiveness Analysis of Stress Cardiovascular Magnetic Resonance Imaging for Stable Chest Pain Syndromes" @default.
• W3025282612 cites W130414541 @default.
• W3025282612 cites W1619893722 @default.
• W3025282612 cites W1975868913 @default.
• W3025282612 cites W1977834980 @default.
• W3025282612 cites W1978699138 @default.
• W3025282612 cites W1979871017 @default.
• W3025282612 cites W1989477582 @default.
• W3025282612 cites W2007212157 @default.
• W3025282612 cites W2023755744 @default.
• W3025282612 cites W2026559096 @default.
• W3025282612 cites W2043951092 @default.
• W3025282612 cites W2085175876 @default.
• W3025282612 cites W2102540428 @default.
• W3025282612 cites W2115416118 @default.
• W3025282612 cites W2120972109 @default.
• W3025282612 cites W2126374401 @default.
• W3025282612 cites W2127448855 @default.
• W3025282612 cites W2129884887 @default.
• W3025282612 cites W2131914260 @default.
• W3025282612 cites W2131973318 @default.
• W3025282612 cites W2141312937 @default.
• W3025282612 cites W2149755434 @default.
• W3025282612 cites W2156990362 @default.
• W3025282612 cites W2160414137 @default.
• W3025282612 cites W2164398842 @default.
• W3025282612 cites W2239162925 @default.
• W3025282612 cites W2509098552 @default.
• W3025282612 cites W2519603001 @default.
• W3025282612 cites W2548871054 @default.
• W3025282612 cites W2615022822 @default.
• W3025282612 cites W2791453970 @default.
• W3025282612 cites W2801677840 @default.
• W3025282612 cites W2807081930 @default.
• W3025282612 cites W2951539836 @default.
• W3025282612 cites W4231927329 @default.
• W3025282612 doi "https://doi.org/10.1016/j.jcmg.2020.02.029" @default.
• W3025282612 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32417337" @default.
• W3025282612 hasPublicationYear "2020" @default.
• W3025282612 type Work @default.
• W3025282612 sameAs 3025282612 @default.
• W3025282612 citedByCount "54" @default.
• W3025282612 countsByYear W30252826122020 @default.
• W3025282612 countsByYear W30252826122021 @default.
• W3025282612 countsByYear W30252826122022 @default.
• W3025282612 countsByYear W30252826122023 @default.
• W3025282612 crossrefType "journal-article" @default.
• W3025282612 hasAuthorship W3025282612A5002476423 @default.
• W3025282612 hasAuthorship W3025282612A5018162304 @default.
• W3025282612 hasAuthorship W3025282612A5021117032 @default.
• W3025282612 hasAuthorship W3025282612A5027172114 @default.
• W3025282612 hasAuthorship W3025282612A5028438824 @default.
• W3025282612 hasAuthorship W3025282612A5031206155 @default.
• W3025282612 hasAuthorship W3025282612A5033266914 @default.
• W3025282612 hasAuthorship W3025282612A5034534199 @default.
• W3025282612 hasAuthorship W3025282612A5037038264 @default.
• W3025282612 hasAuthorship W3025282612A5039107780 @default.
• W3025282612 hasAuthorship W3025282612A5043658281 @default.
• W3025282612 hasAuthorship W3025282612A5043965596 @default.
• W3025282612 hasAuthorship W3025282612A5046806152 @default.
• W3025282612 hasAuthorship W3025282612A5049270829 @default.
• W3025282612 hasAuthorship W3025282612A5055948063 @default.
• W3025282612 hasAuthorship W3025282612A5056428329 @default.
• W3025282612 hasAuthorship W3025282612A5059528272 @default.
• W3025282612 hasAuthorship W3025282612A5061713920 @default.
• W3025282612 hasAuthorship W3025282612A5062965204 @default.
• W3025282612 hasAuthorship W3025282612A5065965358 @default.
• W3025282612 hasAuthorship W3025282612A5071887791 @default.
• W3025282612 hasAuthorship W3025282612A5075076342 @default.
• W3025282612 hasAuthorship W3025282612A5084430398 @default.
• W3025282612 hasConcept C126838900 @default.

• next